Get the Stockscreener App
2.765
0.17%
-0.015
Esperion Therapeutics Inc stock is traded at $2.765, with a volume of 3.92M.
It is down -0.17% in the last 24 hours and up +35.38% over the past month.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
See More
Previous Close:
$2.78
Open:
$2.79
24h Volume:
3.92M
Relative Volume:
0.79
Market Cap:
$556.48M
Revenue:
$116.33M
Net Income/Loss:
$-209.25M
P/E Ratio:
-1.3042
EPS:
-2.12
Net Cash Flow:
$-135.49M
1W Performance:
+9.26%
1M Performance:
+35.38%
6M Performance:
+85.02%
1Y Performance:
+57.69%
1-Day Range:
$2.70
$2.82
1-Week Range:
$2.4498
$2.895
52-Week Range:
$0.6925
$3.94
Esperion Therapeutics Inc Stock (ESPR) Company Profile
Name
Esperion Therapeutics Inc
Sector
Phone
734-887-3903
Address
3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI
Compare ESPR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ESPR
Esperion Therapeutics Inc
|
2.76 | 560.51M | 116.33M | -209.25M | -135.49M | -2.12 |
|
ZTS
Zoetis Inc
|
147.20 | 64.82B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.14 | 47.56B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.285 | 43.31B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.66 | 21.67B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
399.49 | 18.23B | 2.99B | 1.21B | 1.13B | 25.06 |
Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-24 | Initiated | Goldman | Neutral |
| Dec-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-20-24 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-20-23 | Resumed | JP Morgan | Neutral |
| Aug-01-23 | Upgrade | Northland Capital | Under Perform → Market Perform |
| Jun-15-23 | Upgrade | BofA Securities | Underperform → Buy |
| Mar-16-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Mar-16-23 | Downgrade | Northland Capital | Market Perform → Under Perform |
| Mar-07-23 | Upgrade | Credit Suisse | Underperform → Neutral |
| Feb-27-23 | Resumed | BofA Securities | Neutral |
| Feb-24-23 | Upgrade | Jefferies | Hold → Buy |
| Feb-03-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Aug-03-22 | Downgrade | Credit Suisse | Neutral → Underperform |
| May-05-22 | Upgrade | JP Morgan | Underweight → Neutral |
| Mar-10-22 | Initiated | H.C. Wainwright | Buy |
| Oct-19-21 | Downgrade | Credit Suisse | Outperform → Neutral |
| Oct-14-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| May-05-21 | Downgrade | Stifel | Buy → Hold |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Mar-11-21 | Initiated | Morgan Stanley | Equal-Weight |
| Feb-12-21 | Downgrade | Jefferies | Buy → Hold |
| Feb-09-21 | Downgrade | Goldman | Neutral → Sell |
| Jan-15-21 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-10-20 | Upgrade | Credit Suisse | Neutral → Outperform |
| Sep-29-20 | Resumed | JP Morgan | Underweight |
| Aug-11-20 | Downgrade | Credit Suisse | Outperform → Neutral |
| Apr-01-20 | Resumed | BofA/Merrill | Buy |
| Mar-17-20 | Upgrade | Citigroup | Neutral → Buy |
| Feb-24-20 | Downgrade | Northland Capital | Outperform → Market Perform |
| Feb-14-20 | Downgrade | Citigroup | Buy → Neutral |
| Sep-16-19 | Upgrade | Goldman | Sell → Neutral |
| May-29-19 | Downgrade | Goldman | Neutral → Sell |
| May-06-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Apr-26-19 | Upgrade | Goldman | Sell → Neutral |
| Mar-13-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-07-19 | Reiterated | Needham | Strong Buy |
| Dec-13-18 | Initiated | Goldman | Sell |
| Oct-29-18 | Upgrade | Northland Capital | Market Perform → Outperform |
| Oct-16-18 | Initiated | BTIG Research | Buy |
| Aug-17-18 | Upgrade | Citigroup | Neutral → Buy |
| Jul-11-18 | Downgrade | Northland Capital | Outperform → Market Perform |
| May-03-18 | Downgrade | JP Morgan | Neutral → Underweight |
| May-02-18 | Downgrade | BofA/Merrill | Buy → Underperform |
View All
Esperion Therapeutics Inc Stock (ESPR) Latest News
Can Esperion Therapeutics Inc. keep up with sector leadersJobs Report & Fast Momentum Stock Entry Tips - خودرو بانک
Esperion Therapeutics (NASDAQ:ESPR) Shares Up 7.1%What's Next? - MarketBeat
Nasdaq Moves: How does Esperion Therapeutics Inc score in quality rankingsNew Guidance & Proven Capital Preservation Tips - خودرو بانک
Price momentum metrics for Esperion Therapeutics Inc. explainedMarket Activity Report & Real-Time Chart Breakout Alerts - newser.com
Two Seas Capital LP Sells 4,615,000 Shares of Esperion Therapeutics, Inc. $ESPR - MarketBeat
Invesco Ltd. Acquires 157,647 Shares of Esperion Therapeutics, Inc. $ESPR - MarketBeat
Graham Capital Management L.P. Has $702,000 Holdings in Esperion Therapeutics, Inc. $ESPR - MarketBeat
Esperion: A Mixture Of Opportunity And Risk: Why I Would Hold For Now - Seeking Alpha
Why is Esperion Therapeutics Inc. stock going upEarnings Overview Summary & Risk Controlled Swing Alerts - Lancaster City Council
Is There Enough Volume to Lift Esperion Therapeutics Inc.2025 Geopolitical Influence & Smart Allocation Stock Tips - beatles.ru
Investors Buy High Volume of Esperion Therapeutics Call Options (NASDAQ:ESPR) - MarketBeat
Candlestick signals on Esperion Therapeutics Inc. stock todayJuly 2025 Review & Comprehensive Market Scan Reports - Newser
How sensitive is Esperion Therapeutics Inc. to inflationJuly 2025 Gainers & Free Community Consensus Stock Picks - خودرو بانک
Market reaction to Esperion Therapeutics Inc.’s recent news2025 Earnings Impact & Short-Term High Return Ideas - Newser
How does Esperion Therapeutics Inc. perform in inflationary periodsJuly 2025 Chart Watch & Safe Entry Point Alerts - خودرو بانک
Will Esperion Therapeutics Inc. stock recover after recent drop2025 Pullback Review & Weekly Market Pulse Alerts - Newser
Wellington Management Group LLP Has $1.10 Million Position in Esperion Therapeutics, Inc. $ESPR - MarketBeat
Combining machine learning predictions for Esperion Therapeutics Inc.Weekly Earnings Recap & Free Expert Approved Momentum Trade Ideas - Newser
Is Esperion Therapeutics Inc. forming a bullish divergenceJuly 2025 Gainers & Free Safe Capital Growth Stock Tips - خودرو بانک
Esperion Therapeutics Inc. stock chart pattern explained2025 Fundamental Recap & High Accuracy Investment Signals - Newser
Reversal indicators forming on Esperion Therapeutics Inc. stockPortfolio Performance Report & Fast Entry High Yield Tips - Newser
Top 2 Health Care Stocks That May Plunge This Month - Benzinga
Is Esperion Therapeutics Inc. still a buy after recent gainsJuly 2025 Analyst Calls & Risk Controlled Daily Trade Plans - خودرو بانک
Is this a good reentry point in Esperion Therapeutics Inc.Earnings Recap Report & Long-Term Safe Investment Plans - Newser
Published on: 2025-09-05 06:44:23 - Newser
Esperion Therapeutics shares rise 2.77% premarket after presenting at Cantor. - AInvest
Esperion Therapeutics’ Path to Profitability and Global Expansion in the Cardiovascular Space - AInvest
Best data tools to analyze Esperion Therapeutics Inc. stockMarket Movement Recap & Risk Controlled Swing Trade Alerts - Newser
Analyzing recovery setups for Esperion Therapeutics Inc. investorsJuly 2025 Gainers & Precise Buy Zone Identification - Newser
What the charts say about Esperion Therapeutics Inc. todayBuy Signal & Safe Capital Preservation Plans - Newser
Signal strength of Esperion Therapeutics Inc. stock in tech scannersWeekly Profit Analysis & Fast Entry and Exit Trade Plans - Newser
Why Did Esperion Therapeutics Inc (ESPR) Soar 15.23% on Positive Q2 Earnings? - AInvest
Using flow based indicators on Esperion Therapeutics Inc.July 2025 PreEarnings & Precise Buy Zone Identification - Newser
What institutional flow reveals about Esperion Therapeutics Inc.July 2025 Institutional & Long-Term Investment Growth Plans - Newser
Will Esperion Therapeutics Inc. benefit from macro trendsQuarterly Earnings Summary & Reliable Intraday Trade Alerts - Newser
Can Esperion Therapeutics Inc. scale operations efficientlyJuly 2025 Action & Fast Gaining Stock Reports - خودرو بانک
Developing predictive dashboards with Esperion Therapeutics Inc. data2025 Performance Recap & AI Driven Stock Reports - Newser
Should you hold or exit Esperion Therapeutics Inc. nowJuly 2025 Movers & AI Optimized Trade Strategies - Newser
Real time pattern detection on Esperion Therapeutics Inc. stockPortfolio Value Summary & Growth Focused Stock Pick Reports - Newser
Tools to monitor Esperion Therapeutics Inc. recovery probabilityJuly 2025 Reactions & Fast Exit/Entry Strategy Plans - Newser
Technical analysis overview for Esperion Therapeutics Inc. stockWeekly Trade Summary & Weekly High Return Forecasts - Newser
Is Esperion Therapeutics Inc. benefiting from innovation trendsQuarterly Profit Review & AI Powered Buy/Sell Recommendations - khodrobank.com
Esperion Therapeutics Inc Stock (ESPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Esperion Therapeutics Inc Stock (ESPR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Halladay Benjamin | Chief Financial Officer |
Jul 17 '25 |
Sale |
1.11 |
11 |
12 |
474,462 |
2.68%
0.30%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):